California drug maker Gilead Sciences Inc., with operations in Branford, no longer has to post warnings about possible liver injury on its Letairis brand treatment for pulmonary arterial hypertension.
Gilead said Friday the federal Food and Drug Administration’s approval of the change to its box warning label for the oral tablets is good news for the drug and its consumers.
Patients taking the drug also no longer have to undergo monthly liver-function tests, the company said. But Gilead says it will continue to provide testing to patients enrolled in its Letairis-users education program.
